尽管阿司匹林深深植根于最古老的医学史,这种药物的作用机制在几十年前才被发现。阿司匹林有几个适应症,从其长期已知的镇痛和解热特性到最近发现的抗血栓形成,化学预防和抗子痫作用。此外,最近的一项研究确定阿司匹林是一种具有潜在肝病适应症的药物。本文重点介绍了非酒精性脂肪性肝病/非酒精性代谢功能障碍脂肪肝/代谢功能障碍相关脂肪肝病(NAFLD/MAFLD/MASLD)领域。为此,总结并讨论了最近发表的阿司匹林用于非肝硬化MASLD的随机对照试验.此外,先前的流行病学证据支持阿司匹林发挥抗脂肪变性和抗纤维化肝作用的观点,这可能导致肝细胞癌的一级预防,也解决了。接下来,检查了所涉及的假定机制,参考阿司匹林对脂肪组织和肝脏的影响和性别差异的作用。结论是,这些关于阿司匹林作为“肝病药”的新发现值得进一步深入评估。
虽然阿司匹林是医学史的一部分,它的作用机制是几十年前才发现的。阿司匹林可用于治疗疼痛,发烧,炎症和血液倾向于过度凝固(高凝)以及预防某些类型的癌症的病症。此外,最近的研究已经确定了阿司匹林在所谓的脂肪肝疾病中的潜在的肝脏适应症和有益作用,这是由于疾病会破坏身体的正常代谢功能和疾病(如肥胖和糖尿病)。本文讨论了最近发表的一项研究,同时也讨论了以前的研究,支持阿司匹林可能具有抗脂肪肝及其进展为瘢痕组织(肝纤维化和肝硬化)的药理作用,并预防最常见类型的原发性肝癌。阿司匹林不仅作用于防止出血的血细胞(即,血小板),但也靶向其他组织,如脂肪组织和肝脏。重要的是,生物性别可能会影响阿司匹林的药理作用。总的来说,我们文章中总结的发现证明了对阿司匹林作为肝病领域“新型”药物的进一步研究。
Although aspirin is deeply rooted in the most ancient history of medicine, the mechanism of action of this drug was only identified a few decades ago. Aspirin has several indications ranging from its long-known analgesic and antipyretic properties to the more recently discovered antithrombotic, chemopreventive and anti-eclampsia actions. In addition, a recent line of research has identified aspirin as a drug with potential hepatologic indications. This article specifically focuses on the nonalcoholic fatty liver disease/nonalcoholic metabolic dysfunction fatty liver disease/metabolic dysfunction-associated steatotic liver disease (NAFLD/MAFLD/MASLD) field. To this end, the most recently published randomized controlled trial on aspirin for non-cirrhotic MASLD is summarized and discussed. Moreover, previous epidemiologic evidence supporting the notion that aspirin exerts antisteatotic and antifibrotic hepatic effects, which may result in the primary prevention of hepatocellular carcinoma, is also addressed. Next, the putative mechanisms involved are examined, with reference to the effects on adipose tissue and liver and sex differences in the action of aspirin. It is concluded that these novel findings on aspirin as a \"hepatologic drug\" deserve additional in-depth evaluation.
Although aspirin is part of the history of medicine, its mechanism of action was only discovered a few decades ago. Aspirin can be used to treat pain, fever, inflammation and conditions where the blood tends to clot excessively (hypercoagulate) as well as for the prevention of certain types of cancer. Additionally, recent research has identified potential hepatologic indications and beneficial actions of aspirin among the so-called fatty liver disorders owing to conditions which disrupt the body’s regular metabolic functions and disorders (such as obesity and diabetes). This article discusses a recently published study while also addressing previous studies supporting the notion that aspirin might have pharmacologic action against fatty liver and its progression to scarring tissue (liver fibrosis and hepatic cirrhosis) and prevent the most common type of primary liver cancer. Aspirin not only acts on the blood cells that protect against hemorrhage (i.e., the platelets) but also targets other tissues such as adipose tissue and the liver. Importantly, biologic sex may affect the pharmacologic action of aspirin. Collectively, the discoveries summarized in our article justify additional investigations into aspirin as a “novel” drug in the hepatologic field.